ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

NVCN Neovasc Inc

30.03
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Neovasc Inc NASDAQ:NVCN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 30.03 27.70 30.00 0 01:00:00

Neovasc to Report Third Quarter 2021 Financial Results on November 9, 2021

01/11/2021 1:05pm

GlobeNewswire Inc.


Neovasc (NASDAQ:NVCN)
Historical Stock Chart


From May 2021 to May 2024

Click Here for more Neovasc Charts.

via NewMediaWire – Neovasc Inc. (NASDAQ, TSX: NVCN), will report financial results for the quarter ended September 30, 2021 on Tuesday, November 9, 2021. Neovasc’s President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company’s results at 4:30 pm EDT on November 9, 2021.

Interested parties may access the conference call by dialing (877)-407-9208 or (201)-493-6784 (International) and reference Conference ID 13723809. Participants wishing to join the call via webcast should use the link posted on the investor relations section of the Neovasc website at https://www.neovasc.com/investors/.

A replay of the webcast will be available approximately 30 minutes after the conclusion of the call using the link on the Neovasc website. 

About Neovasc Inc.

Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. The Company is a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina. Its products include the Neovasc Reducer™, for the treatment of refractory angina, which is not currently commercially available in the United States (2 U.S. patients have been treated under Compassionate Use) and has been commercially available in Europe since 2015, and Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. For more information, visit: www.neovasc.com. 

InvestorsMike CavanaughWestwicke/ICR Phone: +1.617.877.9641Mike.Cavanaugh@westwicke.com 

MediaSean LeousWestwicke/ICR Phone: +1.646.677.1839Sean.Leous@icrinc.com 

1 Year Neovasc Chart

1 Year Neovasc Chart

1 Month Neovasc Chart

1 Month Neovasc Chart

Your Recent History

Delayed Upgrade Clock